Investment Rating - The report maintains an "Outperform" rating for the company with a target price of RMB 57.68, indicating a potential upside from the current price of RMB 49.90 [1][8]. Core Insights - The company is solidifying its rehabilitation core business while expanding into the emerging medical aesthetics energy source market. The report highlights the company's strategic upgrades in technology platforms and product lines, which are expected to drive future growth [1][8]. - Despite a weak consumption recovery, the forecasted EPS for 2025-2026 is RMB 1.28 and RMB 1.51, with an additional forecast of RMB 1.81 for 2027. The company is positioned in emerging sectors like medical aesthetics and rehabilitation robotics, suggesting potential for a second growth phase [1][8]. Financial Summary - Revenue for 2024 is projected at RMB 400 million, a decrease of 13.45% from the previous year. The net profit attributable to shareholders is expected to be RMB 102 million, down 25.16% [4][8]. - By product line for 2024: electrical stimulation revenue is RMB 37 million (-41.75%), magnetic stimulation is RMB 172 million (-13.92%), electrophysiology is RMB 65 million (+0.25%), consumables and accessories are RMB 79 million (+4.14%), and laser radiofrequency is RMB 30 million (-20.87%) [4][8]. - The company is focusing on core product upgrades and expansion in rehabilitation, with significant developments in electrical stimulation and magnetic stimulation products expected to be certified in 2024 [4][8]. Emerging Market Strategy - The company is increasing investments in emerging fields, particularly in the medical aesthetics energy source market. It has developed products such as shaping magnets, picosecond lasers, and radiofrequency devices, targeting gynecology, dermatology, and medical aesthetics [4][8]. - Sales breakthroughs are anticipated in maternal and child channels and light medical aesthetics markets for 2024, with the Nd:YAG frequency-doubled picosecond laser already certified [4][8].

Core Points - The company board received a resignation application from Vice President Zhong Yiqun due to reaching the legal retirement age [1] - After retirement procedures are completed, Zhong will continue to work as a management consultant for the "Weisi Medical Headquarters R&D Economic Park Project" [1] - Zhong holds 34,125 shares, representing 0.04% of the company's total share capital, and will comply with relevant regulations regarding share management post-resignation [1][2] Summary of Related Sections - Zhong Yiqun has adhered to laws and company regulations during her tenure, and the board expresses gratitude for her contributions to the company's development [2] - The resignation will not impact the company's operations [1]

南京伟思医疗科技股份有限公司 关于高级管理人员退休辞任的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 南京伟思医疗科技股份有限公司（以下简称"公司"）董事会于近日收到公 司副总经理钟益群女士提交的申请，因已到法定退休年龄,申请辞去公司副总经 理的职务。钟益群女士退休手续办理完毕后，公司将以退休返聘的形式继续聘用 钟益群女士担任公司"伟思医疗总部研发经济园项目"建设等工作的管理顾问， 除此之外，将不再担任公司或子公司任何其他职务。根据法律法规、规范性文件 及《中华人民共和国公司法》等有关规定，钟益群女士的辞职报告自送达公司董 事会之日起生效，其辞任不会对公司的生产经营产生影响。 截至本公告日，钟益群女士直接持有公司股份 34,125 股，占公司总股本的 则》《上海证券交易所上市公司股东及董事、监事、高级管理人员减持股份实施 细则》等相关法律法规，管理其所持有股份，严格履行做出的各项承诺。 钟益群女士在担任公司副总经理期间，严格遵守法律法规及《公司章程》 的有关规定，忠实履行作出的声明及承诺，恪尽职守，勤勉尽责，公司及 ...

截至本公告日，钟益群女士直接持有公司股份 34,125 股，占公司总股本的 0.04%。钟益群女士离任后将继续严格遵守《上海证券交易所科创板股票上市规 则》《上海证券交易所上市公司股东及董事、监事、高级管理人员减持股份实施 细则》等相关法律法规，管理其所持有股份，严格履行做出的各项承诺。 证券代码：688580 证券简称：伟思医疗 公告编号：2025-017 南京伟思医疗科技股份有限公司 关于高级管理人员退休辞任的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 钟益群女士在担任公司副总经理期间，严格遵守法律法规及《公司章程》 的有关规定，忠实履行作出的声明及承诺，恪尽职守，勤勉尽责，公司及公司董 事会对钟益群女士在任职期间为公司经营发展所做出的卓越贡献表示衷心感谢！ 特此公告。 南京伟思医疗科技股份有限公司董事会 2025年5月16日 南京伟思医疗科技股份有限公司（以下简称"公司"）董事会于近日收到公 司副总经理钟益群女士提交的申请，因已到法定退休年龄,申请辞去公司副总经 理的职务。钟益群女士退休手续办理完毕后，公司 ...

1、列入本激励计划首次授予激励对象名单的人员具备《中华人民共和国公司法》（以下简称"《公司 法》"）、《南京伟思医疗科技股份有限公司章程》等法律、法规和规范性文件规定的任职资格。 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 2025年4月24日，南京伟思医疗科技股份有限公司（以下简称"公司"）第四届董事会第三次会议、第四 届监事会第三次会议审议通过了《关于〈公司2025年限制性股票激励计划（草案）〉及其摘要的议案》 等相关议案。根据《上市公司股权激励管理办法》（以下简称"《管理办法》"）的相关规定，公司对 2025年限制性股票激励计划首次授予激励对象名单在公司内部进行了公示。公司监事会结合公示情况对 拟激励对象进行了核查，相关公示情况及核查情况如下： 一、公示情况及核查方式 1、公司对激励对象的公示情况 公司于2025年4月25日在上海证券交易所网站（www.sse.com.cn）上披露了《公司2025年限制性股票激 励计划（草案）》（以下简称"本激励计划"）及其摘要、《公司2025年限制性股票激励计划实施考核管 理办 ...

本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 董监高持有的基本情况 截至本公告披露日，南京伟思医疗科技股份有限公司（以下简称"公司"） 董事、副总经理、财务总监陈莉莉女士直接持有公司股份 30,625 股，占公司总 股本的比例为 0.0320%；核心技术人员、副总经理仇凯先生直接持有公司股份 136,500 股，占公司总股本的比例为 0.1425%。 减持计划的主要内容 证券代码：688580 证券简称：伟思医疗 公告编号：2025-016 南京伟思医疗科技股份有限公司 股东及董监高减持股份计划公告 公司于 2025 年 5 月 8 日收到上述 2 名股东《关于股份减持计划的告知函》， 具体内容如下： 董事、副总经理、财务总监陈莉莉女士计划根据市场情况拟通过集中竞价交 易方式减持公司股份数量不超过 7,656 股，即不超过公司股份总数的 0.0080%； 核心技术人员、副总经理仇凯先生计划根据市场情况拟通过集中竞价交易方式减 持公司股份数量不超过 34,125 股，即不超过公司股份总数的 0. ...

南京伟思医疗科技股份有限公司 2024 年年度股东大会会议资料 证券代码：688580 证券简称：伟思医疗 南京伟思医疗科技股份有限公司 2024年年度股东大会会议资料 2025 年 5 月 南京伟思医疗科技股份有限公司 2024 年年度股东大会会议资料 2024 年年度股东大会会议资料目录 | 2024 | 年年度股东大会会议须知 2 | | --- | --- | | 2024 | 年年度股东大会会议议程 4 | | 议案 | 1：关于公司《2024 年度董事会工作报告》的议案 6 | | 议案 | 2：关于公司《2024 年度监事会工作报告》的议案 7 | | 议案 | 3：关于公司《2024 年度财务决算报告》的议案 8 | | 议案 | 4：关于公司《2025 年度财务预算报告》的议案 9 | | 议案 | 5：关于公司《2024 年年度报告及其摘要》的议案 10 | | 议案 | 6：关于续聘会计师事务所的议案 11 | | 议案 | 7：关于公司董事 2025 年度薪酬方案的议案 14 | | 议案 | 8：关于公司监事 2025 年度薪酬方案的议案 15 | | 议案 | 9：关于 2024 ...

2025 年 4 月 24 日，南京伟思医疗科技股份有限公司（以下简称"公司"） 第四届董事会第三次会议、第四届监事会第三次会议审议通过了《关于<公司 2025 年限制性股票激励计划（草案）>及其摘要的议案》等相关议案。根据《上 市公司股权激励管理办法》（以下简称"《管理办法》"）的相关规定，公司对 2025 年限制性股票激励计划首次授予激励对象名单在公司内部进行了公示。公司监事 会结合公示情况对拟激励对象进行了核查，相关公示情况及核查情况如下： 一、公示情况及核查方式 证券代码：688580 证券简称：伟思医疗 公告编号：2025-015 南京伟思医疗科技股份有限公司 监事会关于公司 2025 年限制性股票激励计划 首次授予激励对象名单的审核意见及公示情况说明 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 1、公司对激励对象的公示情况 公司于 2025 年 4 月 25 日在上海证券交易所网站（www.sse.com.cn）上披露 了《公司 2025 年限制性股票激励计划（草案）》（以下简称"本激励计划"）及其 摘要、 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [2] Core Views - The company's cornerstone business remains stable, while the medical aesthetics segment is expected to grow significantly [5][8] - In 2024, the company reported a revenue of 400 million yuan, a decrease of 13.45%, and a net profit of 102 million yuan, down 25.16% [5][6] - The first quarter of 2025 showed a revenue increase of 9.40% year-on-year, with net profit growth of 52.71% [6][7] Financial Performance Summary - 2024 revenue: 400 million yuan, down 13.45% year-on-year - 2024 net profit: 102 million yuan, down 25.16% year-on-year - 2025 Q1 revenue: 96 million yuan, up 9.40% year-on-year - 2025 Q1 net profit: 33 million yuan, up 52.71% year-on-year [5][6][7] Business Segment Insights - The cornerstone business, including mental health, pelvic floor, and rehabilitation, is currently stable, but the medical aesthetics sector is anticipated to see rapid growth [8][10] - The company has a strong market share in pelvic floor rehabilitation and is expanding into new areas such as medical aesthetics and urology [8][10] Future Projections - Revenue projections for 2025-2027 are 473 million yuan, 561 million yuan, and 668 million yuan, with year-on-year growth rates of 18.2%, 18.6%, and 19.1% respectively [11] - Net profit projections for the same period are 134 million yuan, 160 million yuan, and 192 million yuan, with growth rates of 31.8%, 19.2%, and 20.0% respectively [11] Valuation Metrics - Expected EPS for 2025-2027 are 1.40 yuan, 1.67 yuan, and 2.01 yuan, with corresponding P/E ratios of 31x, 26x, and 22x [11]

Investment Rating - The investment rating for the company is not explicitly stated in the provided documents, but the analysis suggests a positive outlook based on growth projections and new product launches [1][2]. Core Viewpoints - The company experienced a revenue decline of 13.45% in 2024, with total revenue of 400 million yuan, but showed recovery in Q1 2025 with a revenue increase of 9.40% to 96 million yuan and a net profit growth of 52.71% to 33 million yuan [1][2]. - The company is focusing on new product launches in the rehabilitation and medical aesthetics sectors, which are expected to drive future growth [2]. - The company has set ambitious revenue growth targets of at least 18% and 40% for 2025 and 2026, respectively, as part of its stock incentive plan, indicating strong growth confidence [2]. Financial Performance Summary - In 2024, the company reported total revenue of 400 million yuan, a decrease of 13.45% year-on-year, with net profit of 102 million yuan, down 25.16% [3]. - For Q1 2025, the company achieved revenue of 96 million yuan, reflecting a year-on-year increase of 9.40%, and net profit of 33 million yuan, up 52.71% [1][2]. - Revenue projections for 2025-2027 are 474 million, 560 million, and 661 million yuan, with corresponding year-on-year growth rates of 18.5%, 18.2%, and 18.0% [2][3]. Product Development and Market Strategy - The company is enhancing its core rehabilitation business while expanding into medical aesthetics, with new products like the navigation transcranial magnetic stimulation device and high-frequency ablation device expected to contribute to revenue growth [2]. - The company has successfully launched new products in the medical aesthetics sector, which are gaining traction in the market and are anticipated to drive significant revenue growth [2]. Earnings Forecast - The forecasted net profits for 2025, 2026, and 2027 are 132 million, 156 million, and 184 million yuan, with year-on-year growth rates of 29.9%, 17.8%, and 17.9% respectively [3]. - The projected price-to-earnings ratios for 2025, 2026, and 2027 are 31, 27, and 23 times, respectively, based on the closing price as of April 25, 2025 [2][3].